Improving attrition rates in Ebola virus drug discovery

Bibliography

• World Health Organization Ebola response team. EBOV disease in West Africa – the first 9 months of the epidemic and forward projections. N Engl J Med 2014;371(16):1481–95
   PubMed Web of Science ®Google Scholar
• Pedrique B, Strub-Wourgaft N, Some C, et al. The drug and vaccine landscape for neglected diseases (2000-11): a systematic assessment. Lancet Glob Health 2013;1(6):e371–9
   PubMed Web of Science ®Google Scholar
• Report of an advisory panel WHO. Ethical considerations for use of unregistered interventions for Ebola viral disease. World Health Organization 2014; WHO/HIS/KER/GHE/14.1. Available from: http://www.who.int/csr/resources/publications/ebola/ethical-considerations/en/ [Last Accessed 23 June 2015]
   Google Scholar
• World Health Organization. WHO Consultation on Potential Ebola Therapies and Vaccines: Background Document for Participants. World Health Organization; Geneva, Switzerland: 2014
   Google Scholar
• McCarthy M. US signs contract with ZMapp maker to accelerate development of the Ebola drug. BMJ 2014;349:g5488
   PubMed Web of Science ®Google Scholar
• Veljkovic V, Loiseau PM, Figadere B, et al. Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection. F1000Res 2015;4:34
   Google Scholar
• Sangawa H, Komeno T, Nishikawa H, et al. Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob Agents Chemother 2013;57(11):5202–8
   PubMed Web of Science ®Google Scholar
• Oestereich L, Ludtke A, Wurr S, et al. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 2014;105:17–21
   PubMed Web of Science ®Google Scholar
• Smither SJ, Eastaugh LS, Steward JA, et al. Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model. Antiretroviral Res 2014;105:153–5
   Web of Science ®Google Scholar
• McCarthy M. FDA allows second experimental drug to be tested in Ebola patients. BMJ 2014;349:g5103
   PubMed Web of Science ®Google Scholar
• Gowen BB, Smee DF, Wong MH, et al. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS One 2008;3:e3725
   PubMed Web of Science ®Google Scholar
• Iverson PL, Warren TK, Wells JB, et al. Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. Viruses 2012;4:2806–30
   PubMed Web of Science ®Google Scholar
• Xu W, Edwards MR, Borek DM, et al. Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1. Cell Host Microbe 2014;16:187–200
   PubMed Web of Science ®Google Scholar
• Kouznetsova J, Sun W, Martı’nez-Romero C, et al. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg Microb 2014;3:e84
   PubMed Web of Science ®Google Scholar
• Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad- spectrum nucleoside analogue BCX4430. Nature 2014;508:402–5
   PubMed Web of Science ®Google Scholar
• Bishop BM. Potential and emerging treatment options for EBOV disease. Ann Pharmacother 2015;49:196–206
   PubMed Web of Science ®Google Scholar
• West TE, von Saint André-von Arnim A. Clinical presentation and management of severe EBOV disease. Ann Am Thorac Soc 2014;11:1341–50
   Google Scholar
• Choi JH, Croyle MA. Emerging targets and novel approaches to EBOV prophylaxis and treatment. BioDrugs 2013;27:565–83
   PubMed Web of Science ®Google Scholar
• Nanbo A, Watanabe S, Halfmann P, Kawaoka Y. The spatio-temporal distribution dynamics of EBOV proteins and RNA in infected cells. Nature 2013;3:1206
   Google Scholar
• Yonezawa A, Cavrois M, Greene WC. Studies of EBOV glycoprotein-mediated Entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha. J Virol 2005;79(2):918–26
   PubMed Web of Science ®Google Scholar
• Volchkov VE, Feldmann H, Volchkova VA, Klenk HD. Processing of the EBOV glycoprotein by the proprotein convertase furin. PNAS 1998;95:5762–7
   PubMed Web of Science ®Google Scholar
• Simmons G, Wool-Lewis R, Baribaud F, et al. EBOV glycoproteins induce global surface protein down-modulation and loss of cell adherence. J Virol 2002;76(5):2518–28
   PubMed Web of Science ®Google Scholar
• Volchkov VE, Becker S, Vochkova VA, et al. GP mRNA of EBOV is edited by the EBOV polymerase and by T7 and vaccinia virus polymerases. Virology 1995;214:421–30
   PubMed Web of Science ®Google Scholar
• Mohan GS, Li W, Ye L, et al. Antigenic subversion: a novel mechanism of host immune evasion by EBOV. PLoS Pathog 2012;8(12):e1003065
   PubMed Web of Science ®Google Scholar
• Basler CF. A novel mechanism of immune evasion mediated by EBOV soluble glycoprotein. Expert Rev Anti Infect Ther 2013;11(5):475–8
   PubMed Web of Science ®Google Scholar
• Jasenosky LD, Neumann G, Lukashevich I, Kawaoka Y. EBOV VP40-induced particle formatin and association with the lipid bIlayer. J Virol 2001;75(11):5205–14
   PubMed Web of Science ®Google Scholar
• Huang Y, Xu L, Sun Y, Nabel GJ. The assembly of EBOV nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Mol Cell 2002;10(2):307–16
   PubMed Web of Science ®Google Scholar
• Hoenen T, Groseth A, Kolesnikova L, et al. Infection of naïve target cells with virus-like particles: implications for the function of EBOV VP24. J Virol 2006;80(14):7260–4
   PubMed Web of Science ®Google Scholar
• Mühlberger E, Weik M, Volchkov VE, et al. Comparison of the transcription and replication strategies of Marburg virus and EBOV by using artificial replication systems. J Virology 1999;73:2333–42
   PubMed Web of Science ®Google Scholar
• Carette JE, Raaben M, Wong AC, et al. EBOV entry requires the cholesterol transporter Niemann-Pick C1. Nature 2011;477(7364):340–3
   PubMed Web of Science ®Google Scholar
• Côté M, Misasi J, Ren T, et al. Small molecule inhibitors reveal Niemann- Pick C1 is essential for Ebola virus infection. Nature 2011;477:344–8
   PubMed Web of Science ®Google Scholar
• Kondratowicz AS, Lennemann NJ, Sinn PL, et al. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc Natl Acad Sci U S A 2011;108:8426–31
   PubMed Web of Science ®Google Scholar
• Veljkovic V, Glisic S, Muller CP, et al. In silico analysis suggests interaction between Ebola virus and the extracellular matrix. Front Microbiol 2015;6:135
   Web of Science ®Google Scholar
• Picazo E, Giordanetto F. Small molecule inhibitors of ebola virus infection. Drug Discov Today 2015;20:277–86
   PubMed Web of Science ®Google Scholar
• DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:151–85
   PubMed Web of Science ®Google Scholar
• Madrid PB, Chopra S, Manger ID, et al. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One 2013;8:e60579
   PubMed Web of Science ®Google Scholar
• Johansen LM, Brannan JM, Delos SE, et al. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med 2013;5(190):190ra79
   PubMed Web of Science ®Google Scholar
• DiMasi JA. Risk in new investigational drugs. Clin Pharma Therapeutics 2001;69:297–306
   PubMed Web of Science ®Google Scholar
• McGee P. Modeling success with in silico tools. Drug Discov Today 2005;8:23–8
   Google Scholar
• Veljkovic N, Glisic S, Perovic V, et al. The role of long-range interactions in discovery of new drugs. Exp Opin Drug Disc 2011;6:1263–70
   PubMed Web of Science ®Google Scholar
• The DrugBank database. Available from: http://www.drugbank.ca [Last Accessed 9 June 2015]
   Google Scholar
• World Health Organization. Guidelines for the treatment of malaria. 3rd edition. Geneva: 2015
   Google Scholar
• Veljkovic V, Goeijenbier M, Glisic S, et al. In silico analysis suggests repurposing of ibuprofen for prevention and treatment of EBOLA virus disease. F1000Res 2015;4:104
   Google Scholar
• Virtual screen for candidate inhibitors of EBOLA virus infection. BioMed Consulting. Available from: http://www.biomedconsulting.info/ebola_screen.php [Last Accessed 9 June 2015]
   Google Scholar
• Varkey JB, Shantha JG, Crozier I, et al. Persistence of Ebola virus in ocular fluid during convalescence. New Engl J Med 2015;372(25):2423–7
   PubMed Web of Science ®Google Scholar
• Christia A, Davies-Wayne GJ, Cordier-Lasalle T, et al. Possible sexual transmission of Ebola virus - Liberia 2015. MMWR Morb Mortal Wkly Rep 2015;64(17):479–81
   PubMed Web of Science ®Google Scholar